GERMANTOWN, Md., Oct. 14 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. (Nasdaq and ArcaEx(R): AVRX) today announced that Kenneth C. Carter, Ph.D., President and CEO is scheduled to present at the BIO InvestorForum at The Palace Hotel in San Francisco on Wednesday, October 19th. The presentation will begin at 2:00 pm PDT (5:00 pm EDT) in the Presidio Room. The presentation will be webcast live and can be accessed at http://www.avalonrx.com/ under Investor Relations / Upcoming Presentations. The webcast will also be archived for 90 days following the presentation. About Avalon Pharmaceuticals Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. Avalon seeks to discover and develop novel therapeutics through the use of a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis which it calls AvalonRx(R). Avalon Pharmaceuticals was established in 1999 and is headquartered in Germantown, Maryland. This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in particular, related to Avalon's ability to close its initial public offering and, if its is able to close the offering, the level of its share price, which may decline, and other statements about its research and development activities, including development of AVN944, its collaboration agreements, and its ability to successfully complete preclinical and clinical testing. Such statements reflect the current views of Avalon management and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, risks and uncertainties. All forward looking statements are qualified in their entirety by this cautionary statement and the company undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Contacts: Avalon Pharmaceuticals Gary Lessing Chief Financial Officer Tel: (301) 556-9828 Fax: (301) 556-9910 Email: Wendy Lau Noonan Russo Tel: (212) 845-4272 Email: DATASOURCE: Avalon Pharmaceuticals, Inc. CONTACT: Gary Lessing, Chief Financial Officer of Avalon Pharmaceuticals, +1-301-556-9828, Fax: +1-301-556-9910, ; or Wendy Lau of Noonan Russo, +1-212-845-4272, Web site: http://www.avalonrx.com/

Copyright